A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.

被引：2
|
作者：
Garcia, Agustin A.
Hays, John L.
Cote, Gregory Michael
Becerra, Carlos
Langleben, Adrian
Lau, Susie K.
Roman, Lynda D.
McCormick, Colleen Catherine
Richards, Donald A.
Braiteh, Fadi S.
Yimer, Habte Aragaw
Richey, Stephen Lane
Edenfield, William Jeffery
Kossler, Kimiko
Hume, Stephanie
Li, Youzhi
Hitron, Matthew
Li, Chiang
机构：
[1] Univ Southern Calif, Los Angeles Cty Hosp, Los Angeles, CA USA
[2] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA
[5] St Marys Hosp, Westmount, PQ, Canada
[6] McGill Univ, Montreal, PQ, Canada
[7] Johns Hopkins Univ Hosp, Portland, OR USA
[8] McKesson Specialty Hlth, Tyler Canc Ctr, US Oncol Res, Houston, TX USA
[9] McKesson Specialty Hlth, US Oncol Network, The Woodlands, TX USA
[10] Texas Oncol, Tyler, TX USA
[11] McKesson Specialty Hlth, Texas Oncol, US Oncol Network, Houston, TX USA
[12] Univ Med Ctr, Greenville Hosp Syst, Inst Translat Oncol Res, Greenville, SC USA
[13] Boston Biomed Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5578
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Preliminary results of a phase II study of gemcitabine and epirubicin in platinum-resistant or refractory advanced ovarian cancer.
    Arcuri, C
    Sorio, R
    Caffo, O
    Scalone, S
    Griso, C
    Lucenti, A
    Valdurga, F
    Frisinghelli, M
    Arisi, E
    Galligioni, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 472S - 472S
  • [32] A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
    Wu, Lingying
    Wang, Jing
    Wang, Li
    Lu, Weiguo
    Wang, Ke
    Lin, An
    Li, Ning
    Li, Li
    Su, Ning
    Xie, Shuang
    Jiang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders
    Grisham, Rachel N.
    Moore, Kathleen N.
    Gordon, Michael S.
    Harb, Wael
    Cody, Gwendolyn
    Halpenny, Darragh F.
    Makker, Vicky
    Aghajanian, Carol A.
    CLINICAL CANCER RESEARCH, 2018, 24 (22) : 5525 - 5533
  • [34] Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
    Keldsen, N
    Havsteen, H
    Vergote, I
    Bertelsen, K
    Jakobsen, A
    GYNECOLOGIC ONCOLOGY, 2003, 88 (02) : 118 - 122
  • [35] A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.
    Edenfield, William Jeffery
    Becerra, Carlos
    Langleben, Adrian
    Spira, Alexander I.
    Braiteh, Fadi S.
    Kossler, Kimiko
    Gao, Yuan
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Phase IB dose escalation and expansion trial of the oral hedgehog inhibitor sonidegib (LDE225) and weekly paclitaxel in platinum-resistant ovarian cancer (NCT02195973)
    Arend, R. C.
    Bae, S.
    Doo, D. W.
    Alvarez, R. D.
    Straugh, J. M., Jr.
    Bevis, K. S.
    Estes, J. M.
    Landen, C. N., Jr.
    Leath, C. A., III
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 115 - 115
  • [37] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Cannistra, Stephen A.
    Matulonis, Ursula A.
    Penson, Richard T.
    Hambleton, Julie
    Dupont, Jakob
    Mackey, Howard
    Douglas, Jeffrey
    Burger, Robert A.
    Armstrong, Deborah
    Wenham, Robert
    McGuire, William
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5180 - 5186
  • [38] A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer
    Fu, S.
    Burger, R. A.
    Hamilton, E.
    Corr, B. R.
    Naumann, R. W.
    Wenham, R. M.
    Morgan, M. A.
    Stagg, R.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 14 - 15
  • [39] Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
    Nicum, S.
    Holmes, J.
    McGregor, N.
    Dunn, R.
    Collins, L.
    Kaye, S.
    McNeish, I.
    Glasspool, R. M.
    Hall, M.
    Roux, R.
    Michael, A.
    Banerjee, S.
    Kristeleit, R.
    Jayson, G.
    Clamp, A.
    Mansouri, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S725 - S726
  • [40] Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer
    Le, T.
    Hopkins, L.
    Baines, K. A.
    Rambout, L.
    Al Hayki, M.
    Fung, M. Kee Fung
    GYNECOLOGIC ONCOLOGY, 2006, 102 (01) : 49 - 53
12345